A First-in-Human, Randomised, Double Blind, Placebo Controlled, Single and Multiple Ascending Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AJM347 in Healthy Male Caucasian and Japanese Subjects in the Fasted and Fed State
Phase of Trial: Phase I
Latest Information Update: 06 Sep 2018
At a glance
- Drugs AJM 347 (Primary)
- Indications Unspecified
- Focus Adverse reactions; First in man
- Sponsors EA Pharma
- 28 Aug 2018 Status changed from recruiting to completed.
- 17 Jul 2018 Planned End Date changed from 1 Mar 2018 to 1 Sep 2019.
- 17 Jul 2018 Planned primary completion date changed from 1 Aug 2018 to 1 Jul 2018.